Palisade Bio, INC Form 4 insider transactions

Chief Medical Officer Mitchell Lawrence Jones reports acquisition of stock options and restricted stock units in Palisade Bio, Inc.

CEO and CFO of Palisade Bio, John David Finley, reports acquisition of stock options and restricted stock units.

Palisade Bio director Donald Allen Williams acquired 388 shares of common stock through the vesting of restricted stock units.

Director Binxian Wei of Palisade Bio, Inc. acquired 388 shares of common stock through the vesting of restricted stock units.

Director Wei Binxian reports acquisition of stock options in Palisade Bio as part of director compensation.

Director Margery B. Fischbein acquired 2,100 common stock options in Palisade Bio, Inc. as part of director compensation.

Director Donald Allen Williams of Palisade Bio, Inc. received 2,100 common stock options as part of his compensation for services as a director.

Director Binxian Wei reports the vesting and settlement of restricted stock units into 465 shares of Palisade Bio common stock on June 11, 2024.

Director Donald Allen Williams acquired 340 shares of Palisade Bio, Inc. common stock due to the vesting and settlement of restricted stock units.

Mitchell Jones, Chief Medical Officer of Palisade Bio, Inc., reports the vesting and settlement of restricted stock units resulting in the acquisition and disposal of common stock to cover tax obligations.

CEO John Finley reports the vesting and settlement of restricted stock units (RSUs) and subsequent tax withholding, resulting in changes to his beneficial ownership of Palisade Bio stock.

Director Donald Williams of Palisade Bio, Inc. (PALI) purchased 1,000 shares of common stock at $4.863 per share on May 28, 2024.

Palisade Bio's CEO, John David Finley, recently acquired 1,000 shares of the company's common stock at $4.81 per share.

CEO John David Finley reports the acquisition of 666 shares of Palisade Bio, Inc. through the company's Employee Stock Purchase Plan (ESPP) at a price of $4.9725 per share.

CEO Mitchell Jones reports the vesting and settlement of restricted stock units (RSUs) and subsequent tax withholding, resulting in changes to his beneficial ownership of Palisade Bio stock.

CEO John Finley reports the vesting of restricted stock units and subsequent tax withholding, affecting his beneficial ownership of Palisade Bio stock.

CEO John Finley reports the vesting and settlement of restricted stock units and subsequent acquisition of common stock in Palisade Bio, Inc.